The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
 
Robert L. Ferris
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly; Merck; Pfizer
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; VentiRx
 
Lisa Licitra
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Debiopharm Group; Eisai; Merck Serono; MSD; Novartis; Roche; SOBI
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Debiopharm Group; Merck Serono; SOBI
 
Jérôme Fayette
Leadership - Glycotope GmbH
Honoraria - AstraZeneca; Bristol-Myers Squibb
 
Caroline Even
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Innate Pharma; Merck Serono; MSD
 
George R. Blumenschein
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Merck
Research Funding - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Merck; Novartis; Xcovery
 
Kevin Harrington
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Pfizer
Research Funding - MSD
 
Joel Guigay
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MERCK SERONO (Inst)
 
Everett E. Vokes
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Leidos Biomedical Research; Lilly; Merck; Merck Serono; Regeneron; Takeda; VentiRx
 
Nabil F. Saba
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly; Merck; Pfizer
 
Robert I. Haddad
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Merck; Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst); VentiRx (Inst)
 
Shanmugasundaram Ramkumar
No Relationships to Disclose
 
Jeffrey Russell
No Relationships to Disclose
 
Peter Brossart
No Relationships to Disclose
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck Serono; Takeda
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Manish Monga
Employment - Bristol-Myers Squibb
 
Jin Zhu
Employment - Bristol-Myers Squibb
 
A. Dimitrios Colevas
Stock and Other Ownership Interests - Gilead Sciences; Pharmacyclics
Research Funding - Bristol-Myers Squibb; Curis; Genentech
 
Maura L. Gillison
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Lilly; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Lilly; Merck
Research Funding - AstraZeneca; Bristol-Myers Squibb; Kyowa Hakko Kirin; Merck
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Lilly; Merck